Phosphorylated ERBB2 TMD/JMD heterodimers bind SHC1

Stable Identifier
R-HSA-9665701
Type
Reaction [binding]
Species
Homo sapiens
Compartment
cytosol, plasma membrane
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
Phosphorylated ERBB2 TMD/JMD heterodimers bind SHC1
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
Activation of downstream RAS signaling was shown for ERBB2 S653C (de Martino et al. 2014) and ERBB2 R678Q (Bose et al. 2013, de Martino et al. 2014) through activating tyrosine phosphorylation on ERKs (MAPK1 and MAPK3) and SHC1. It is assumed that heterodimers of ERBB2 TMD/JMD mutants, like the wild type ERBB2 heterodimers, bind SHC1.
Literature References
PubMed ID Title Journal Year
24971884 Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib

Rieken, M, Xylinas, E, Klatte, T, Shariat, SF, Rouprêt, M, Elemento, O, Clozel, T, Zhuang, D, Krzywinski, M, de Martino, M

Cancer Biol. Ther. 2014
23220880 Activating HER2 mutations in HER2 gene amplification negative breast cancer

Bose, R, Shen, W, Aronson, AB, Goel, N, Koboldt, DC, Li, S, Searleman, AC, Ma, CX, Ellis, MJ, Shen, D, Ding, L, Monsey, J, Mardis, ER, Kavuri, SM

Cancer Discov 2013
Participants
Input
Output
Participates
as an event of
Normal reaction
SHC1 binds phosphorylated ERBB2 heterodimers (Homo sapiens)
Functional status

Gain of function of p-6Y-ERBB2 TMD/JMD mutants (RAS):Ligand-Activated p-EGFR,p-ERBB3,(p-ERBB4) [plasma membrane]

Normal Entity
Disease Entity
Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Orlic-Milacic, M  (2019-10-31)
Reviewed
Bose, R  (2019-10-25)
Kancha, RK  (2019-11-03)
Krishna, A  (2019-10-25)
Created
Orlic-Milacic, M  (2019-10-31)
Cite Us!